Physician profile
Scott A Sweeney
NPI 1659372811
$2,153.37
in general payments reported to CMS, 2019-2025
20 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.52 · 2022: $392 · 2023: $450 · 2024: $719 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $257.89 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $256.24 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $216.14 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.73 | 2022-2024 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $213.34 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $168.48 | 2022-2025 | Evenity, Prolia, Otezla |
| Phathom Pharmaceuticals, INC. | $134.82 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $110.16 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $101.81 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $100.08 | 2022-2025 | Farxiga, Breztri |
| Abbvie INC. | $98.24 | 2023-2025 | Vraylar |
| Exact Sciences Corporation | $68.78 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $43.05 | 2024 | Intellis Adaptivestim |
| Aimmune Therapeutics, INC. | $33.85 | 2025 | Vowst |
| Bayer Healthcare Pharmaceuticals INC. | $29.28 | 2023-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.12 | 2023 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $24.38 | 2023 | Prehevbrio |
| Alexion Pharmaceuticals, INC. | $21.00 | 2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $16.52 | 2023 | Eliquis |
| Sumitomo Pharma America, INC. | $16.46 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.